NCT04690855: A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)

NCT04690855
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor, Therapeutic antibody, Immunotherapy, Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least one previous line of systemic treatment in the advanced setting with or without immune therapy
Exclusions: Patients who have a germline (hereditary) BRCA mutation; Patients who have received more than two previous lines of systemic treatment in the advanced setting with or without immune therapy; Patients who have received previous PARP inhibitor treatment (e.g. talazoparib, niraparib, olazaparib); Patients with previous radiation to the metastases to be treated with radiation on this protocol; Patients with symptomatic, untreated, or actively progressing CNS metastases – see trial for details; Patients with a history of leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04690855

Comments are closed.

Up ↑